Quick Answer
REGENXBIO Inc. reported R&D Expense of $228.30 million for fiscal year 2025.
REGENXBIO Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $228.30M | +9.5% |
| 2024 | $208.52M | -10.2% |
| 2023 | $232.27M | -4.2% |
| 2022 | $242.45M | +33.6% |
| 2021 | $181.44M | +9.1% |
| 2020 | $166.29M | +33.9% |
| 2019 | $124.19M | +48.1% |
| 2018 | $83.87M | +46.6% |
| 2017 | $57.22M | +25.8% |
| 2016 | $45.48M | +163.2% |
| 2015 | $17.28M | +248.3% |
| 2014 | $4.96M | -1.8% |
| 2013 | $5.05M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $56.10M | +3.1% | -5.7% |
| June 30, 2025 | $59.50M | +21.8% | +12.1% |
| March 31, 2025 | $53.09M | -3.2% | -2.5% |
| September 30, 2024 | $54.43M | -6.5% | +11.4% |
| June 30, 2024 | $48.87M | -18.4% | -10.9% |
| March 31, 2024 | $54.84M | -6.3% | -5.7% |
| September 30, 2023 | $58.18M | -8.1% | -2.8% |
| June 30, 2023 | $59.89M | -1.8% | +2.3% |
- REGENXBIO Inc. showed an increase of +9.5% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, REGENXBIO Inc.’s r&d expense has grown by 4419.9% (from $5.05 million to $228.30 million).
- The most recent figure is from REGENXBIO Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: